Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 1/20 | 0.57 |
| ▸ | FLT3 | P36888 | 1/20 | 0.57 |
| ▸ | EGFR | P00533 | 9/20 | 0.54 |
| ▸ | FLT1 | P17948 | 5/20 | 0.52 |
| ▸ | ULK1 | O75385 | 2/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.46 |
| ▸ | SYK | P43405 | 3/20 | 0.45 |
| ▸ | KDR | P35968 | 3/20 | 0.44 |
| ▸ | IGF1R | P08069 | 1/20 | 0.43 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1641747 | 0.89 | FGFR2 (0.67) | FGFR2FLT3EGFRFLT1ULK1 | |
| SCHEMBL1641640 | 0.78 | FGFR2 (0.65) | FGFR2FLT3EGFRFLT1ULK1 | |
| SCHEMBL8231000 | 0.75 | EGFR (0.58) | FGFR2FLT3EGFRFLT1PRKCI | |
| SCHEMBL7185783 | 0.74 | EGFR (0.53) | FGFR2FLT3EGFRFLT1ULK1 | |
| SCHEMBL1642621 | 0.74 | FGFR2 (0.81) | FGFR2FLT3EGFRFLT1PRKCI | |
| Akn-028 SCHEMBL1642669 | 0.73 | FGFR2 (1.00) | FGFR2FLT3EGFRFLT1ULK1 | |
| SCHEMBL1640884 | 0.73 | FGFR2 (0.76) | FGFR2FLT3EGFRFLT1PRKCI | |
| Akn-028 SCHEMBL31060922 | 0.73 | FGFR2 (1.00) | FGFR2FLT3EGFRFLT1ULK1 | |
| SCHEMBL7021509 | 0.72 | EGFR (0.70) | EGFRFLT1KDR | |
| SCHEMBL2744897 | 0.72 | SYK (0.60) | FGFR2FLT3EGFRULK1PRKCI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8436171-B2 | Amino substituted pyrazines as inhibitors or protein kinases | AKINION PHARMACEUTICALS AB (SE) | 2013-05-07 | — | — | US | disclosed |
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | BIOVITRUM AB (SE) | 2011-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098310-A1 | NOVEL COMPOUNDS, USE AND PREPARATION THEREOF | FLT3, MLLT1, MYD88 | FGFR2 329/4885FLT3 1/4885EGFR 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.